Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Jacob Drobnyk Soumerai, M.D.


Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Bantilan KS, Kay NE, Parikh SA, Rabe KG, Call TG, Leis JF, Ding W, Slager SL, Soumerai JD, Roeker LE, Mato A, Zelenetz AD. Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selection. Leuk Lymphoma. 2022 Dec 12; 1-12. PMID: 36503412.
    Citations:    Fields:    
  2. Miller KC, Johnson PC, Abramson JS, Soumerai JD, Yee AJ, Branagan AR, O'Donnell EK, Saucier A, Jacobson CA, Frigault MJ, Raje NS. Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. Blood Cancer J. 2022 11 01; 12(10):146. PMID: 36316312; PMCID: PMC9622902.
    Citations:    Fields:    Translation:Humans
  3. Soumerai JD, Rosenthal A, Harkins S, Duffy J, Mecca C, Wang Y, Grewal RK, El-Jawahri AR, Liu H, Menard C, Dogan A, Yang L, Rimsza LM, Bantilan K, Martin H, Lei M, Mohr S, Kurilovich A, Kudryashova O, Postovalova E, Nardi V, Abramson JS, Chiarle R, Zelenetz AD, Louissaint A. Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma. Blood. 2022 10 20; 140(16):1822-1826. PMID: 35802834; PMCID: PMC9837428.
    Citations:    Fields:    
  4. Soumerai JD, Takvorian RW, Sohani AR, Abramson JS, Ferry JA. Venetoclax activity in a patient with central nervous system involvement by chronic lymphocytic leukaemia. Lancet Haematol. 2022 10; 9(10):e796. PMID: 36174642.
    Citations:    Fields:    Translation:Humans
  5. Roeker LE, Feldman TA, Soumerai JD, Falco V, Panton G, Dorsey C, Zelenetz AD, Falchi L, Park JH, Straus DJ, Pena Velasquez C, Lebowitz S, Fox Y, Battiato K, Laudati C, Thompson MC, McCarthy E, Kdiry S, Martignetti R, Turpuseema T, Purdom M, Paskalis D, Miskin HP, Sportelli P, Leslie LA, Mato AR. Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach. Clin Cancer Res. 2022 09 15; 28(18):3958-3964. PMID: 35852793; PMCID: PMC9481719.
    Citations:    Fields:    
  6. Soumerai JD. Case 16-2022: A Man with Fevers, Night Sweats, and a Mediastinal Mass. Reply. N Engl J Med. 2022 08 25; 387(8):763-764. PMID: 36001728.
    Citations:    Fields:    Translation:Humans
  7. Pagel JM, Soumerai JD, Reddy N, Jagadeesh D, Stathis A, Asch A, Salman H, Kenkre VP, Iasonos A, Llorin-Sangalang J, Li J, Zelenetz AD. Zandelisib with continuous or intermittent dosing as monotherapy or in combination with rituximab in patients with relapsed or refractory B-cell malignancy: a multicentre, first-in-patient, dose-escalation and dose-expansion, phase 1b trial. Lancet Oncol. 2022 08; 23(8):1021-1030. PMID: 35835137.
    Citations:    Fields:    
  8. Fajgenbaum DC, Goiffon RJ, Soumerai JD, Harris CK. Case 16-2022: A 55-Year-Old Man with Fevers, Night Sweats, and a Mediastinal Mass. N Engl J Med. 2022 05 26; 386(21):2036-2048. PMID: 35613025.
    Citations:    Fields:    Translation:Humans
  9. Siddiqi T, Soumerai JD, Dorritie KA, Stephens DM, Riedell PA, Arnason J, Kipps TJ, Gillenwater HH, Gong L, Yang L, Ogasawara K, Thorpe J, Wierda WG. Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. Blood. 2022 03 24; 139(12):1794-1806. PMID: 34699592.
    Citations: 4     Fields:    Translation:HumansCTClinical Trials
  10. Haydu JE, Maron JS, Redd RA, Gallagher KME, Fischinger S, Barnes JA, Hochberg EP, Johnson PC, Takvorian RW, Katsis K, Portman D, Ruiters J, Sechio S, Devlin M, Regan C, Blumenthal KG, Banerji A, Judd AD, Scorsune KJ, McGree BM, Sherburne MM, Lynch JM, Weitzman JI, Lei M, Kotton CN, Dighe AS, Maus MV, Alter G, Abramson JS, Soumerai JD. Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study. Blood Adv. 2022 03 22; 6(6):1671-1683. PMID: 35073571; PMCID: PMC8789382.
    Citations: 2     Fields:    Translation:HumansCellsCTClinical Trials
  11. Fischer T, Ni A, Bantilan KS, Soumerai JD, Alperovich A, Batlevi C, Younes A, Zelenetz AD. The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma. Leuk Lymphoma. 2022 03; 63(3):573-582. PMID: 35109746.
    Citations:    Fields:    Translation:Humans
  12. Soumerai JD, Mato AR, Dogan A, Seshan VE, Joffe E, Flaherty K, Carter J, Hochberg E, Barnes JA, Hamilton AM, Abramson JS, Batlevi CL, Matasar MJ, Noy A, Owens CN, Palomba ML, Kumar A, Takvorian T, Ni A, Choma M, Friedman C, Chadha P, Simkins E, Ruiters J, Sechio S, Portman D, Ramos L, Nolet N, Mahajan N, Martignetti R, Mi J, Scorsune K, Lynch J, McGree B, Hughes S, Grieve C, Roeker LE, Thompson M, Johnson PC, Roshal M, Huang J, Biondo J, Wu Q, Jacob A, Abdel-Wahab O, Zelenetz AD. Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2021 Dec; 8(12):e879-e890. PMID: 34826411; PMCID: PMC9326222.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  13. Batlevi CL, Sha F, Alperovich A, Ni A, Smith K, Ying Z, Soumerai JD, Caron PC, Falchi L, Hamilton A, Hamlin PA, Horwitz SM, Joffe E, Kumar A, Matasar MJ, Moskowitz AJ, Moskowitz CH, Noy A, Owens C, Palomba LM, Straus D, von Keudell G, Zelenetz AD, Seshan VE, Younes A. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020 07 17; 10(7):74. PMID: 32678074.
    Citations: 21     Fields:    Translation:HumansPHPublic Health
  14. Soumerai JD, Ni A, Alperovich A, Batlevi C, Bantilan KS, Fischer T, Copeland AR, Smith K, Ying Z, Younes A, Zelenetz AD. Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma. Leuk Lymphoma. 2020 12; 61(12):2939-2946. PMID: 32666852.
    Citations:    Fields:    Translation:Humans
  15. Treon SP, Castillo JJ, Skarbnik AP, Soumerai JD, Ghobrial IM, Guerrera ML, Meid K, Yang G. The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients. Blood. 2020 05 21; 135(21):1912-1915. PMID: 32302379; PMCID: PMC7243149.
    Citations: 131     Fields:    Translation:HumansCellsPHPublic Health
  16. Soumerai JD, Ni A, Darif M, Londhe A, Xing G, Mun Y, Kay NE, Shanafelt TD, Rabe KG, Byrd JC, Chanan-Khan AA, Furman RR, Hillmen P, Jones J, Seymour JF, Sharman JP, Ferrante L, Mobasher M, Stark T, Reddy V, Dreiling LK, Bhargava P, Howes A, James DF, Zelenetz AD. Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. Lancet Haematol. 2019 Jul; 6(7):e366-e374. PMID: 31109827; PMCID: PMC6620111.
    Citations: 15     Fields:    Translation:Humans
  17. Soumerai JD, Davids MS, Werner L, Fisher DC, Armand P, Amrein PC, Neuberg D, Hochberg EP, Brown JR, Abramson JS. Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2019 12; 60(12):2931-2938. PMID: 31074316.
    Citations: 2     Fields:    Translation:HumansCTClinical Trials
  18. Soumerai JD, Tajmir SH, Hirsch MS, Massoth LR. Case 7-2019: A 73-Year-Old Woman with Swelling of the Right Groin and Fever. N Engl J Med. 2019 Feb 28; 380(9):859-868. PMID: 30811914.
    Citations:    Fields:    Translation:HumansCells
  19. Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV, Schwaiblmair MH, Soumerai JD, Takvorian RW, Hochberg EP, Barnes JA, Abramson JS, Frigault MJ, Dietrich J. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019 05 16; 133(20):2212-2221. PMID: 30808634.
    Citations: 67     Fields:    Translation:Humans
  20. Soumerai JD, Ni A, Xing G, Huang J, Furman RR, Jones J, Sharman JP, Hallek M, Adewoye AH, Dubowy R, Dreiling L, Zelenetz AD. Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. Leuk Lymphoma. 2019 06; 60(6):1438-1446. PMID: 30407886; PMCID: PMC6545166.
    Citations: 3     Fields:    Translation:HumansCells
  21. Soumerai JD, Zelenetz AD, Moskowitz CH, Palomba ML, Hamlin PA, Noy A, Straus DJ, Moskowitz AJ, Younes A, Matasar MJ, Horwitz SM, Portlock CS, Konner JA, Gounder MM, Hyman DM, Voss MH, Fury MG, Gajria D, Carvajal RD, Ho AL, Beumer JH, Kiesel B, Zhang Z, Chen A, Little RF, Jarjies C, Dang TO, France F, Mishra N, Gerecitano JF. The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. Clin Cancer Res. 2017 Aug 01; 23(15):4119-4126. PMID: 28314788; PMCID: PMC5541854.
    Citations: 10     Fields:    Translation:HumansCTClinical Trials
  22. Bledsoe JR, Redd RA, Hasserjian RP, Soumerai JD, Nishino HT, Boyer DF, Ferry JA, Zukerberg LR, Harris NL, Abramson JS, Sohani AR. The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome. Am J Hematol. 2016 10; 91(10):E436-41. PMID: 27419920.
    Citations: 11     Fields:    Translation:Humans
  23. Soumerai JD, Sohani AR, Abramson JS. Diagnosis and management of Castleman disease. Cancer Control. 2014 Oct; 21(4):266-78. PMID: 25310208.
    Citations: 51     Fields:    Translation:Humans
  24. Soumerai JD, Hellmann MD, Feng Y, Sohani AR, Toomey CE, Barnes JA, Takvorian RW, Neuberg D, Hochberg EP, Abramson JS. Treatment of primary mediastinal B-cell lymphoma with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone is associated with a high rate of primary refractory disease. Leuk Lymphoma. 2014 Mar; 55(3):538-43. PMID: 23734654.
    Citations: 31     Fields:    Translation:Humans
  25. Treon SP, Soumerai JD, Hunter ZR, Patterson CJ, Ioakimidis L, Kahl B, Boxer M. Long-term follow-up of symptomatic patients with lymphoplasmacytic lymphoma/Waldenström macroglobulinemia treated with the anti-CD52 monoclonal antibody alemtuzumab. Blood. 2011 Jul 14; 118(2):276-81. PMID: 21566092; PMCID: PMC3138682.
    Citations: 7     Fields:    Translation:HumansCTClinical Trials
  26. Treon SP, Ioakimidis L, Soumerai JD, Patterson CJ, Sheehy P, Nelson M, Willen M, Matous J, Mattern J, Diener JG, Keogh GP, Myers TJ, Boral A, Birner A, Esseltine DL, Ghobrial IM. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009 Aug 10; 27(23):3830-5. PMID: 19506160.
    Citations: 67     Fields:    Translation:HumansCTClinical Trials
  27. Ioakimidis L, Patterson CJ, Hunter ZR, Soumerai JD, Manning RJ, Turnbull B, Sheehy P, Treon SP. Comparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009 Mar; 9(1):62-6. PMID: 19362976.
    Citations: 12     Fields:    Translation:Humans
  28. Leleu X, Tamburini J, Roccaro A, Morel P, Soumerai J, Lévy V, Wemeau M, Balkaran S, Poulain S, Hunter ZR, Ghobrial IM, Treon SP, Leblond V. Balancing risk versus benefit in the treatment of Waldenström's Macroglobulinemia patients with nucleoside analogue-based therapy. Clin Lymphoma Myeloma. 2009 Mar; 9(1):71-3. PMID: 19362978.
    Citations: 8     Fields:    Translation:Humans
  29. Leleu X, Hunter ZR, Xu L, Roccaro AM, Moreau AS, Santos DD, Hatjiharissi E, Bakthavachalam V, Adamia S, Ho AW, Soumerai J, Patterson CJ, Manning RJ, Hamilton S, Verselis S, Fox E, Carrasco R, Ghobrial IM, Treon SP. Expression of regulatory genes for lymphoplasmacytic cell differentiation in Waldenstrom Macroglobulinemia. Br J Haematol. 2009 Apr; 145(1):59-63. PMID: 19220283.
    Citations: 7     Fields:    Translation:HumansCells
  30. Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L, Chu L, Musto P, Baron AD, Nunnink JC, Kash JJ, Terjanian TO, Hyman PM, Nawfel EL, Sharon DJ, Munshi NC, Anderson KC. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res. 2009 Jan 01; 15(1):355-60. PMID: 19118065.
    Citations: 27     Fields:    Translation:HumansCTClinical Trials
  31. Leleu X, Soumerai J, Roccaro A, Hatjiharissi E, Hunter ZR, Manning R, Ciccarelli BT, Sacco A, Ioakimidis L, Adamia S, Moreau AS, Patterson CJ, Ghobrial IM, Treon SP. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009 Jan 10; 27(2):250-5. PMID: 19064987.
    Citations: 35     Fields:    Translation:Humans
  32. Treon SP, Branagan AR, Ioakimidis L, Soumerai JD, Patterson CJ, Turnbull B, Wasi P, Emmanouilides C, Frankel SR, Lister A, Morel P, Matous J, Gregory SA, Kimby E. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood. 2009 Apr 16; 113(16):3673-8. PMID: 19015393; PMCID: PMC2670786.
    Citations: 31     Fields:    Translation:HumansCTClinical Trials
  33. Leleu X, Xu L, Jia X, Sacco A, Farag M, Hunter ZR, Moreau AS, Ngo HT, Hatjiharissi E, Ho AW, Santos DD, Adamia S, O'Connor K, Ciccarelli B, Soumerai J, Manning RJ, Patterson CJ, Roccaro AM, Ghobrial IM, Treon SP. Endoplasmic reticulum stress is a target for therapy in Waldenstrom macroglobulinemia. Blood. 2009 Jan 15; 113(3):626-34. PMID: 18981296.
    Citations: 9     Fields:    Translation:HumansCells
  34. Treon SP, Soumerai JD, Branagan AR, Hunter ZR, Patterson CJ, Ioakimidis L, Briccetti FM, Pasmantier M, Zimbler H, Cooper RB, Moore M, Hill J, Rauch A, Garbo L, Chu L, Chua C, Nantel SH, Lovett DR, Boedeker H, Sonneborn H, Howard J, Musto P, Ciccarelli BT, Hatjiharissi E, Anderson KC. Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood. 2008 Dec 01; 112(12):4452-7. PMID: 18713945; PMCID: PMC2597120.
    Citations: 28     Fields:    Translation:HumansCTClinical Trials
  35. Moreau AS, Jia X, Patterson CJ, Roccaro AM, Xu L, Sacco A, O'Connor K, Soumerai J, Ngo HT, Hatjiharissi E, Hunter ZR, Ciccarelli B, Manning R, Ghobrial IM, Leleu X, Treon SP. The HMG-CoA inhibitor, simvastatin, triggers in vitro anti-tumour effect and decreases IgM secretion in Waldenstrom macroglobulinaemia. Br J Haematol. 2008 Sep; 142(5):775-85. PMID: 18537966.
    Citations: 6     Fields:    Translation:Humans
  36. Hatjiharissi E, Ciccarelli BT, Ioakimidis L, Borok R, Soumerai JD, Manning RJ, Hunter ZR, Xu L, Patterson CJ, Alvin S, Treon SP. Serum Immunoglobulin free light chains as markers of disease burden and response to treatment in patients with Waldenstrom's macroglobulinemia. J Clin Oncol. 2008 May 20; 26(15_suppl):8617. PMID: 27950406.
  37. Ciccarelli BT, Hatjiharissi E, Soumerai JD, Hunter ZR, Ioakimidis L, Patterson CJ, Manning RJ, Xu L, Adamia S, Treon SP. Use of soluble CD27 as a marker of disease burden and the effect of rituximab-induced IgM flare and plasmapheresis in patients with Waldenström's macroglobulinemia. J Clin Oncol. 2008 May 20; 26(15_suppl):8585. PMID: 27951147.
  38. Hunter ZR, Ioakimidis L, Soumerai JD, Patterson CJ, Xu L, Leleu X, Ciccarelli BT, Sacco A, Adamia S, Hatjiharissi E, Treon SP. Increased prevalence of monoclonal gammopathy, abnormal immunoglobulin levels, and recurrent infections in family members of patients with familial Waldenstrom's macroglobulinemia. J Clin Oncol. 2008 May 20; 26(15_suppl):8540. PMID: 27951175.
  39. Ho AW, Hatjiharissi E, Ciccarelli BT, Branagan AR, Hunter ZR, Leleu X, Tournilhac O, Xu L, O'Connor K, Manning RJ, Santos DD, Chemaly M, Patterson CJ, Soumerai JD, Munshi NC, McEarchern JA, Law CL, Grewal IS, Treon SP. CD27-CD70 interactions in the pathogenesis of Waldenstrom macroglobulinemia. Blood. 2008 Dec 01; 112(12):4683-9. PMID: 18216294; PMCID: PMC2597134.
    Citations: 19     Fields:    Translation:HumansAnimalsCells
  40. Treon SP, Hatjiharissi E, Leleu X, Moreau AS, Roccaro A, Hunter ZR, Soumerai JD, Ciccarelli B, Xu L, Sacco A, Ngo HT, Jia X, Yang C, Adamia S, Branagan AR, Ho AW, Santos DD, Tournilhac O, Manning RJ, Leduc R, O'Connor K, Nelson M, Patterson CJ, Ghobrial I. Novel agents in the treatment of Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2007 Aug; 7 Suppl 5:S199-206. PMID: 17877845.
    Citations: 6     Fields:    Translation:HumansAnimals
  41. Leleu X, O'Connor K, Ho AW, Santos DD, Manning R, Xu L, Hatjiharissi E, Moreau AS, Branagan AR, Hunter ZR, Dimmock EA, Soumerai J, Patterson C, Ghobrial I, Treon SP. Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. Am J Hematol. 2007 Jan; 82(1):83-4. PMID: 16955461.
    Citations: 9     Fields:    Translation:HumansCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Soumerai's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (173)
Co-Authors (54)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.